Read more

BREAKING : Strong declines on Wall Street - Gilead drug rejected in phase I testing

6:29 PM 23 April 2020
In the last minutes we have been observing a strong declines on Wall Street. This is linked to recent rumors that a Gilead drug called Remdesivir, which showed the most promising initial results in the treatment of  coronavirus, was rejected in phase I tests. S&P 500 retreats from around 2830 points, below 2790 points. Gilead's stock is currently losing 2%. This information was provided by the Financial Times.
S&P 500 dropped sharpy lower after information regarding coronavirus drug hit the markets. Source: xStation5
Share:
Back

Market News

01.07.2025
15:00

BREAKING: ISM Manufacturing slightly above estimates

03:00 PM BST, United States - ISM Data for June: ISM Manufacturing PMI: actual 49.0; forecast 48.8; previous 48.5; ISM...

 14:54

🟡Gold Gains Over 1.3%

The precious metal has risen over 1.3% today, testing the vicinity of $3350 per ounce. Furthermore, it has recovered above the support zone associated...

 10:42

Chart of the day: USDJPY (01.07.2025)

The US dollar is exceptionally weak, recording its worst half-year performance since 1973 – since the beginning of 2025, it has already lost about...
More news

Join over 1 600 000 XTB Group Clients from around the world

Start trading Download the app Download the app
The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits